The ASX biotech IPO market has been quiet for much of 2025, but Epiminder broke through the lull last week with a substantial listing. The Cochlear-backed company, which has developed the sub-scalp electroencephalogram (EEG) device Minder, raised $125 million in its December 1 debut — a large result for a year in which few early-stage life sciences companies have approached the boards.
The stock’s performance since then has been uneven. Epiminder began trading at $1.31, slid to $1.00 by December 5, and has gradually recovered. Shares last changed hands at $1.22, up 2.1% on Wednesday and around 4.7% over the past week. The rebound suggests the market is finding a more considered footing after the initial volatility, though the stock remains well below the $1.50 offer price.
Fresh broker research this week has added another lens for investors. Morgans initiated coverage with a speculative buy rating and a $2.33 price target, arguing that the company is addressing a clearly defined diagnostic gap in epilepsy care and that the long-duration monitoring enabled by Minder could shift diagnostic pathways for a meaningful subset of patients.
A diagnostic gap shaped by EEG limitations
Epilepsy specialists have long worked within the constraints of short-form EEG testing, which captures only a fraction of a patient’s real-world neurological activity. Minder takes a fundamentally different approach: implanted beneath the scalp, it records continuously for months or years, producing a far richer data set for clinicians who need to confirm seizure patterns, characterise events or refine therapy decisions.
This design initially targets a segment of drug-resistant epilepsy patients who repeatedly receive inconclusive EEG results — a group Epiminder estimates at roughly 45,000 in the US each year. The associated market opportunity, around US$1.1 billion annually, is built not on speculative expansion but on an existing diagnostic bottleneck that clinicians and payers already recognise.
Deliverables, timelines and the US launch pathway
While Minder already holds US Food and Drug Administration clearance, Epiminder now faces a different kind of challenge: demonstrating real-world performance, preparing next-generation hardware and assembling a commercial presence in the United States.
IPO proceeds will fund the DETECT demonstration study, development of the G1 Minder system and early US commercial build-out. According to Morgans, two milestones stand out on the near-term horizon: the targeted release of the G0 device and the formal launch of DETECT, both expected in the second half of 2026. These will likely anchor the company’s narrative over the next 18–24 months as investors look for tangible progress before the US rollout begins.
A financial trajectory typical of pre-commercial med-tech
Epiminder enters life as a listed company with financials that reflect its stage of development. Revenue contribution is expected to remain modest until the US launch begins in 2H26 and scales over several years.
This pattern is typical for med-tech scale-ups introducing a new diagnostic category: early capital allocation is weighted towards clinical validation, engineering improvements and market preparation rather than immediate sales. For investors, that means progress markers ahead of the launch — such as device releases, study initiations and operational milestones — are likely to matter more to valuation than top-line numbers in the next couple of reporting periods.
A read on where ASX biotech sentiment stands
Epiminder’s debut captures the tensions in today’s ASX biotech market. Investors are clearly willing to back differentiated clinical technology — the size of the raise shows that — but they are equally clear about the need for near-term milestones and disciplined capital plans. The softer trading after listing reflects that dynamic rather than a rejection of the technology or market opportunity.
With few biotech IPOs expected this year, Epiminder now functions as a bellwether of sorts. Its progress through 2026 — not only in share price, but in study launches, device iterations and early commercial steps — will give investors a clearer signal of how selective the market intends to be with med-tech growth stories in the year ahead.